Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Selexis signs agreement with Zyngenia
Zyngenia is a privately held biotherapeutics company focused on the development of next-generation multi-specific antibody-based therapeutics. Selexis co-founder and CEO Igor Fisch said that they are excited to
Zyngenia is a privately held biotherapeutics company focused on the development of next-generation multi-specific antibody-based therapeutics. Selexis co-founder and CEO Igor Fisch said that they are excited to
Pro-Pharmaceuticals’ operating loss was $1.21m, compared to $1.25m for the comparable period in 2009. For the nine months ended 30 September 2010 Pro-Pharmaceuticals posted a net loss of
According to Inovio Pharmaceuticals, the decrease in the respective periods were mainly due to no revenue being recognised under the terminated Wyeth collaboration and licensing agreement as a
In a 24-week, placebo-controlled, monotherapy study of the impact of Cycloset on glycemic control in 159 overweight adults (BMI = 26.0kg/m2 for males and = 28.0kg/m2 for females)
ICON said that with this alliance it is strengthening its current biomarker solution to include an integrated suite of labeling, separation and mass spectrometry technologies for protein and
Dalton supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. The company provides
Pozen is expected to receive the milestone as a result of the grant of marketing and pricing approval for Vimovo (naproxen/ esomeprazole magnesium) 500/20mg modified-release tablets in the
arYla is expected to be used to optimise a range of properties critical to the successful development of a therapeutic or diagnostic antibody. The arYla technology results from
BOL-303259-X has been developed for the potential treatment of glaucoma and ocular hypertension and was licensed to Bausch + Lomb by NicOx in March 2010. BOL-303259-X Phase 2b
Pfizer said that the Emphasis-HF trial demonstrated a 37% relative risk reduction for the eplerenone group compared to placebo in the primary composite endpoint of death from CV